

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 14, 2008
(Exact Name of Registrant as Specified in Charter)

DELCATH SYSTEMS, INC.

(Exact Name of Registrant as Specified in Charter)

DELAWARE

(State of Incorporation)

001-16133

(Commission
File Number)

06-1245881

(IRS Employer
Identification No.)

600 FIFTH AVENUE, 23rd FLOOR
NEW YORK, NEW YORK

(Address of Principal Executive Offices)

10020

(Zip Code)

Registrant's telephone number, including area code: (212) 489-2100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective October 14, 2008 (the “Effective Date”), the Board of Directors of Delcath Systems, Inc. (the “Company”) elected Eamonn Hobbs as a Director. Mr. Hobbs election was recommended by the Nominating & Governance Committee and approved by the unanimous action of the full Board of Directors. See Exhibit 99.1 attached hereto for biographical information about Mr. Hobbs.

Mr. Hobbs will receive the director fees and benefits described in the Company’s Proxy Statement filed with the Securities and Exchange Commission on April 24, 2008. In addition, he was awarded on the Effective Date under the Company’s 2004 Stock Incentive Plan (the “Plan”) options to purchase (i) 50,000 shares of the Company’s common stock at an exercise price per share equal to the Fair Market Value thereof on the Effective Date determined in accordance with the Plan, and (ii) 100,000 shares of the Company’s common stock having an exercise price per share equal to 150% of such Fair Market Value. There are no other material transactions between Mr. Hobbs and the Company.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 16, 2008

DEL CATH SYSTEMS, INC.

By: /s/ Paul M. Feinstein

Name: Paul M. Feinstein

Title: Chief Financial Officer

NEW YORK, NY – October 15, 2008 – Delcath Systems, Inc. (Nasdaq: DCTH) today announced the appointment of Mr. Eamonn Hobbs to Delcath's Board of Directors. Mr. Hobbs is President and Chief Executive Officer of AngioDynamics, Inc. (Nasdaq: ANGO), a leading medical device company specializing in the development and sales of medical technology serving the needs of interventional oncologists and vascular interventionalists.

Mr. Hobbs, a Co-Founder of AngioDynamics, built his company into a leading medical technology company with an international market presence with a highly diverse product line. Throughout his tenure at AngioDynamics, Mr. Hobbs has led the Company's efforts in marketing, strategic planning, product development, and general management. In 2004, AngioDynamics was spun off from E-Z-EM, Inc., a company focusing on diagnostic radiology and gastrointestinal technologies, and of which Mr. Hobbs was the Senior Vice-President since 1988. Before his involvement with these companies, Mr. Hobbs was the Director of Marketing and Product Development at NAMIC, Founder, President and CEO of Hobbs Medical, Inc., and a Product Development Engineer at Cook Incorporated.

On joining Delcath's Board of Directors, Mr. Hobbs commented, "This is an exciting time for Delcath, and I am pleased to be joining the Board during this period of growth and expansion. I am impressed with the Company's technology, the promising results of the Phase III Trial, and the excellent management team. I believe that the Company is poised for significantly more growth and success in the emerging market of minimally invasive cancer treatments, and I look forward to leveraging my extensive experience to aid that successful growth."

Mr. Hobbs continues to be highly active in the field of interventional radiology, where he has been named an Honorary Fellow of the Society of Interventional Radiology ("SIR"), is on the SIR Strategic Planning Committee, and is a Member of the Society of Cardiovascular and Interventional Radiology. Mr. Hobbs is a frequent presenter at industry and medical conferences, and sits on the Board of Directors of the Medical Device Manufacturers Association, the Society of Interventional Radiology Foundation, and the American College of Phlebology Foundation.

Commenting on today's announcement, Richard L. Taney, President and Chief Executive Officer of Delcath, stated, "We are delighted to have Eamonn join the Board of Directors of Delcath. His successful leadership of AngioDynamics, his experience within the medical device industry and his involvement in a number of influential medical organizations make him a welcome addition to our Board of Directors. I look forward to working with Mr. Hobbs and the entire Board while we continue our progress in completing our clinical trials."

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company has developed a proprietary, patented system which will improve the efficacy of cancer treatment while reducing the considerable, systemic side-effects of chemotherapy. Delcath's novel drug delivery platform is capable of delivering anti-cancer drugs at very high doses to a specific organ or region of the body while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

This release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the current belief of management. These statements relate to, among other things, the results to date of our phase III clinical trials as described above. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond

our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. These risks and uncertainties include those discussed from time to time in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Contact:

Company Contact:

Delcath Systems, Inc.

Richard L. Taney

(212) 489-2100

rtaney@delcath.com

Investor Relations Contact:

Strategic Growth International, Inc.

Richard E. Cooper

(212) 838-1444

rcooper@sgi-ir.com

Public Relations Contact:

Rubenstein Associates, Inc.

Robin Wagge

(212) 843-8006

rwagge@Rubenstein.com